143 related articles for article (PubMed ID: 28238718)
1. Towards therapeutic advances in melanoma management: An overview.
Singh S; Zafar A; Khan S; Naseem I
Life Sci; 2017 Apr; 174():50-58. PubMed ID: 28238718
[TBL] [Abstract][Full Text] [Related]
2. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
Strickland LR; Pal HC; Elmets CA; Afaq F
Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutics for the treatment of metastatic melanoma.
Mansfield AS; Markovic SN
Future Oncol; 2009 May; 5(4):543-57. PubMed ID: 19450181
[TBL] [Abstract][Full Text] [Related]
4. Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects.
Blokx WA; van Dijk MC; Ruiter DJ
Histopathology; 2010 Jan; 56(1):121-32. PubMed ID: 20055910
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for advanced melanoma: fulfilling the promise.
Gogas H; Polyzos A; Kirkwood J
Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of melanoma: efficacy and mode of action.
Wieder T; Brenner E; Braumüller H; Röcken M
J Dtsch Dermatol Ges; 2016 Jan; 14(1):28-37. PubMed ID: 26713633
[TBL] [Abstract][Full Text] [Related]
7. [Melanoma, from diagnosis to treatment].
Baroudjian B; Pagès C; Lebbé C
Rev Infirm; 2016 Mar; (219):16-8. PubMed ID: 26944639
[TBL] [Abstract][Full Text] [Related]
8. Treatment of melanoma and nonmelanoma skin cancer.
Rass K; Tilgen W
Adv Exp Med Biol; 2008; 624():296-318. PubMed ID: 18348465
[TBL] [Abstract][Full Text] [Related]
9. Novel therapies in melanoma.
Scheier B; Amaria R; Lewis K; Gonzalez R
Immunotherapy; 2011 Dec; 3(12):1461-9. PubMed ID: 22091682
[TBL] [Abstract][Full Text] [Related]
10. [What's new in skin cancers?].
Jouary T
Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755
[TBL] [Abstract][Full Text] [Related]
11. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Leccia MT; Planchamp F; Sassolas B; Combemale P; Modiano P; Bedane C; Cupissol D; Derrey S; Dygai-Cochet I; Lamant L; Lubrano V; Mirabel X; Mourrégot A; Rougé Bugat ME; Siegrist S; Thariat J; Tiffet O; Truc G; Verdoni L; Mazeau-Woynar V
Ann Dermatol Venereol; 2014 Feb; 141(2):111-21. PubMed ID: 24507205
[TBL] [Abstract][Full Text] [Related]
12. Metastatic melanoma treatment: Combining old and new therapies.
Davey RJ; van der Westhuizen A; Bowden NA
Crit Rev Oncol Hematol; 2016 Feb; 98():242-53. PubMed ID: 26616525
[TBL] [Abstract][Full Text] [Related]
13. Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics.
Juszczak AM; Wöelfle U; Končić MZ; Tomczyk M
Med Res Rev; 2022 Jul; 42(4):1423-1462. PubMed ID: 35187675
[TBL] [Abstract][Full Text] [Related]
14. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeted therapy for melanoma.
Friedlander P; Hodi FS
Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
17. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.
Tomei S; Wang E; Delogu LG; Marincola FM; Bedognetti D
Expert Opin Biol Ther; 2014 May; 14(5):663-86. PubMed ID: 24625306
[TBL] [Abstract][Full Text] [Related]
18. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
19. Metastatic melanoma - a review of current and future treatment options.
Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
[TBL] [Abstract][Full Text] [Related]
20. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
